“Skin Clearance, Treatment Response Off-Therapy, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-Week Phase 3 Trial in Adults and Children Down to 2 Years of Age With Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s460. Accessed June 13, 2025. https://skin.dermsquared.com/skin/article/view/3111.